News

In today’s world of sophisticated, complex tests, an evolving relationship between laboratory professionals and clinicians can aid in providing a quicker diagnosis and help to achieve better patient outcomes.

The potential of enzyme cocktails for enhanced mycobacterial infection management.

There is value in leveraging the contributions of nurses, laboratorians, and informaticists in antimicrobial stewardship.

Latest discoveries around HpaA's implications for immune response and disease progression.

The assay, the cobas Malaria test, is manufactured by Roche, and will be available in the United States at the end of Q2 2024.

Insights from a CDC study on challenges and research direction in pediatric hepatitis.

The increase highlights the threat posed by climate change and the need for innovative preparedness, prevention, and mitigation tools.

Bulevirtide's key role in blocking hepatitis virus entry.

The role of the US President’s Emergency Plan for AIDS Relief in combating tuberculosis (TB).

The long-term benefits of antimicrobial use and resistance (AUR) reporting is about improving patient care and combating resistance.

Insights on Sofosbuvir levels in pregnant women.

A new strategy for universal infant immunization in the 2023-2024 RSV season faces implementation and medication access barriers.

The evolution of treatment for hepatitis C virus during the past 15 years has been astounding, and we now are able to talk about how HCV could be eliminated.

The authorization was given to Invivyd’s pemivibart (Pemgarda), and it is indicated for adults and adolescents with moderate-to-severe immune compromised conditions.

Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.

This week learn more about CDC's strategies to reduce waterborne diseases; the US change to a trivalent influenza vaccine; new data for Merck's pneumococcal vaccine; and how PCR testing can influence a patient diagnosis and outcome.

The efficacy of SPIKEVAX from Delta to Omicron protection in pediatric patients.

A cautious approach for now is warranted as well as a need for a randomized clinical trial.

The impact of polymerase chain reaction (PCR) testing on patient outcomes.

Here is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.

Phase 3 trial evaluates the impact of TCVs in high-risk populations.

Investigators find that bacteremia rarely develops from asymptomatic bacteriuria, and that empiric antibiotic treatment should be reserved for those at risk.

Wireless test kit transforms screening efforts towards combating the virus.

Here is a review of therapies for treating this bacterium.

How acute malnutrition undermines Malaria in children under 5 years old.

A large European study looked at a modern-day communication method and its influence on a public health initiative to increase immunizations.

Low-frequency resistant cells in bacterial isolates are challenging to detect and may contribute to unexplained treatment failure.

FDA recalls of specific lots of contaminated products.

The Bill & Melinda Gates Medical Research Institute launches the M72/AS01E vaccine in South Africa to combat TB.

The company’s investigational vaccine, V116, is a conjugate vaccine and demonstrated immunogenicity for all 21 serotypes across the studied adult groups.